A class of novel N-(3S-1,2,3,4-tetrahydroisoquinoline-3-carbonyl)-l-amino acid derivatives: their synthesis, anti-thrombotic activity evaluation, and 3D QSAR analysis

European Journal of Medicinal Chemistry

Volumn 44, Issue 12, 2009, Pages 4904-4919

  Cheng, Shenling ^a   Zhang, Xiaoyi ^a   Wang, Wei ^b   Zhao, Ming ^a   Zheng, Meiqing ^a   Chang, Heng Wei ^b   Wu, Jianghui ^a   Peng, Shiqi ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b C S Bio Company   (United States)

Author keywords

3D QSAR; Anti thrombotic; Modification; Tetrahydroisoquinoline

Indexed keywords

ADENOSINE DIPHOSPHATE; ANTICOAGULANT AGENT; ARACHIDONIC ACID; N (3 1,2,3,4 ETRAHYDROISOQUINOLINE 3 CARBONYL) PHENYLALANINE; N (3 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBONYL) ALANINE; N (3 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBONYL) AMINO ACID DERIVATIVE; N (3 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBONYL) ARGININE; N (3 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBONYL) ASPARAGINE; N (3 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBONYL) ASPARTIC ACID; N (3 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBONYL) CYSTEINE; N (3 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBONYL) GLUTAMIC ACID; N (3 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBONYL) GLUTAMINE; N (3 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBONYL) GLYCINE; N (3 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBONYL) HISTIDINE; N (3 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBONYL) ISOLEUCINE; N (3 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBONYL) LEUCINE; N (3 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBONYL) LYSINE; N (3 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBONYL) METHIONINE; N (3 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBONYL) PROLINE; N (3 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBONYL) SERINE; N (3 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBONYL) THREONINE; N (3 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBONYL) TRYPTOPHAN; N (3 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBONYL) TYROSINE; N (3 1,2,3,4 TETRAHYDROISOQUINOLINE 3 CARBONYL) VALINE; THROMBIN; THROMBOCYTE ACTIVATING FACTOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PROTEIN TRANSPORT; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RAT; THROMBOCYTE AGGREGATION; THROMBOGENESIS;

AMINO ACIDS; ANIMALS; BLOOD PLATELETS; CELLS, CULTURED; FIBRINOLYTIC AGENTS; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; MOLECULAR STRUCTURE; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RATS; SWINE; TETRAHYDROISOQUINOLINES;

EID: 70449646504     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2009.08.002     Document Type: Article

References (43)

1. Ashby B., Daniel J.L., and Smith J.B. Mechanisms of platelet activation and inhibition. Platelets Health Dis 4 (1990) 1-26
2. Davies M.J. A macro and micro view of coronary vascular insult in ischemic heart disease. Circulation 82 (1990) 38-46
3. Davies M.J., and Thomas A.C. Plaque fissuring: the cause of acute myocardial infarction, sudden ischemic death, and crescendo angina. Br. Heart. J. 53 (1985) 363-373
4. FitzGerald D.J., Roy L., Catella F., and FitzGerald G.A. Platelet activation in unstable coronary disease. N. Engl. J. Med. 15 (1986) 983-989
5. Fuster V. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 90 (1994) 2126-2148
6. Fuster V., Steele P.M., and Chesebro J.H. Role of platelets and thrombosis in coronary atherosclerotic disease and sudden death. J. Am. Coll. Cardiol. 5 (1985) 175-184
7. Willerson J.T., Golino P., Eidt J., Campbell W.B., and Buja L.M. Specific platelet mediators and unstable coronary artery lesions: experimental evidence and potential clinical implications. Circulation 80 (1989) 198-205
8. Zhao M., Bi L., Bi W., Wang C., Yang Z., Ju J., and Peng S. Synthesis of new class dipeptide analogues with improved permeability and antithrombotic activity. Bioorg. Med. Chem. 14 (2006) 5711-5720
9. Zheng M., Zhang X., Zhao M., Chang H.W., Wang W., Wang Y., and Peng S. (3S)-N-(l-Aminoacyl)-1,2,3,4-tetrahydroisoquinolines, a class of novel anti-thrombotic agents: synthesis, bioassay, 3D QSAR, and ADME analysis. Bioorg. Med. Chem. 16 (2008) 9574-9587
10. Zhao M., Liu J., Wang C., Wang L., Liu H., and Peng S. Synthesis and biological activity of nitronyl nitroxide containing peptides. J. Med. Chem. 48 (2005) 4285-4292
11. Zhao M., Wang C., Liu J., Zhou K., and Peng S. The composition and sequence specificity of Pro-Ala-Lys-OH for the thrombolytic activities of P6A and related oligopeptides. Bioorg. Med. Chem. 12 (2004) 2275-2286
12. Zhao M., Wang C., Wu Y., Zhou K., and Peng S. Synthesis and thrombolytic activity of carboline-3-carboxylic acid modified metabolites of Ala-Arg-Pro-Ala-Lys. Prep. Biochem. Biotechnol. 34 (2004) 57-76
13. Zhao M., Wang C., Yang J., Liu J., Xu Y., Wu Y., and Peng S. Identification, synthesis and bioassay for the metabolites of P6A. Bioorg. Med. Chem. 11 (2003) 4913-4920
14. Okhamafe A.O., and Arhewoh I.M. An overview of site-specific delivery of orally administered proteins/peptides and modeling considerations. J. Biomed. Sci. 1 (2004) 7-20
15. Petit D.K., and Gombotz W.R. The development of site-specific drug-delivery systems for protein and peptide biopharmaceuticals. Trends. Biotechnol. 16 (1998) 343-349
16. Bai J.P., Chang L.L., and Guo J.H. Targeting of peptide and protein drugs to specific sites in the oral route. Crit. Rev. Ther. Drug. Carrier. Syst. 12 (1995) 339-371
17. Gonzalez J.F., de la Cuesta E., and Avendano C. Synthesis and cytotoxic activity of pyrazino[1,2- b]-isoquinolines, 1-(3-isoquinolyl)isoquinolines, and 6,15-imino- isoquino[3,2- b]-3-benzazocines. Bioorg. Med. Chem. 15 (2007) 112-118
18. H-Lina R., and Abrahama D.J. Identification of a lead pharmacophore for the development of potent nuclear receptor modulators as anticancer and X syndrome disease therapeutic agents. Bioorg. Med. Chem. Lett. 16 (2006) 4178-4183
19. Lane J.W., Estevez A., Mortara K., Callan O., Spencerc J.R., and Williamsa R.M. Antitumor activity of tetrahydroisoquinoline analogues 3-epi-jorumycin and 3-epi-renieramycin G. Bioorg. Med. Chem. Lett. 16 (2006) 3180-3183
20. Kuo C.Y., Wu M.J., and Kuo Y.H. Synthesis and antitumor activity of cis-dichloroplatinum (II) complexes of 1-(2-aminophenyl)-1,2,3,4-tetrahydro- isoquinolines. Eur. J. Med. Chem. 41 (2006) 940-949
21. Iwasa K., Moriyasu M., Tachibana Y., Kim H.S., Wataya Y., Wiegrebe W., Bastow K.F., Cosentino L.M., Kozuka M., and Lee K.-H. Simple isoquinoline and benzylisoquinoline alkaloids as potential antimicrobial, antimalarial, cytotoxic, and anti-HIV agents. Bioorg. Med. Chem. 9 (2001) 2871-2884
22. Rathelotl P., Vanelle P., Gasquetz M., Delmas F., Crozet M.P., Timon-David P., and Maldonadol J. Synthesis of novel functionalized 5nitroisoquinolines and evaluation of in vitro antimalarial activity. Eur. J. Med. Chem. 30 (1995) 503-508
23. Mokrosz M.J., Bojarski A.J., Duszynska B., Tatarczynska E., Klodzinska A., Deren-Wesolek A., Charakchieva-Minol S., and Chojnacka-Wojcik E. 1,2,3,4-Tetrahy- droisoquinoline derivatives: a new class of 5-HT1A receptor ligands. Bioorg. Med. Chem. 7 (1999) 287-295
24. Klopfenstein S.R., Evdokimov A.G., Colson A.-O., Fairweather N.T., Neuman J.J., Maier M.B., Gray J.L., Gerwe G.S., Stake G.E., Howard B.W., Farmer J.A., Pokross M.E., Downs T.R., Kasibhatla B., and Peters K.G. 1,2,3,4-Tetrahy- droisoquinolinyl sulfamic acids as phosphatase PTP1B inhibitors. Bioorg. Med. Chem. Lett. 16 (2006) 1574-1578
25. Hirth B.H., Qiao S., Cuff L.M., Cochran B.M., Pregel M.J., Gregory J.S., Sneddon S.F., and Kane Jr. J.L. Discovery of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid diamides that increase CFTR mediated chloride transport. Bioorg. Med. Chem. Lett. 15 (2005) 2087-2091
26. Li J.J., Wang H., Qu F., Musial C., Tino J.A., Robl J.A., Slusarchyk D., Golla R., Seethala R., Dickinson K., Giupponi L., Grover G., Sleph P., Flynn N., Murphy B.J., Gordon D., Kungc M., and Stoffel R. Tetrahydroisoquinoline 1-carboxamides as growth hormone secretagogues. Bioorg. Med. Chem. Lett. 15 (2005) 1799-1802
27. Mukherjee S., Sahaa A., and Royb K. QSAR of estrogen receptor modulators: exploring selectivity requirements for ERa versus ERb binding of tetrahydroisoqui- noline derivatives using E-state and physicochemical parameters. Bioorg. Med. Chem. Lett. 15 (2005) 957-961
28. Chesworth R., Zawistoski M.P., Lefker B.A., Cameron K.O., Day R.F., Mangano F.M., Rosati R.L., Colella S., Petersen D.N., Brault A., Lu B., Pan L.C., Perry P., Ng O., Castleberry T.A., Owen T.A., Brown T.A., Thompson D.D., and DaSilva-Jardine P. Tetrahydroisoquinolines as subtype selective estrogen agonists/antagonists. Bioorg. Med. Chem. Lett. 14 (2004) 2729-2733
29. Kubota H., Watanabe T., Kakefuda A., Masuda N., Wada K., Ishii N., Sakamoto S., and Tsukamoto S. QSAR of estrogen receptor modulators: exploring selectivity requirements for ERa versus ERb binding of tetrahydroiso- quinoline derivatives using E-state and physicochemical parameters. Bioorg. Med. Chem. Lett. 14 (2004) 3049-3052
30. Okuda K., Kotake Y., and Ohta S. Neuroprotective or neurotoxic activity of 1-methyl-1,2,3,4-tetrahydroisoquinoline and related compounds. Bioorg. Med. Chem. Lett. 13 (2003) 2853-2855
31. ÉSzáricsRiedl Z., Nyikos L., Hajós G., and Kardos J. Interaction of novel condensed triazine derivatives with central and peripheral type benzodiazepine receptors: synthesis, in vitro pharmacology and modelling. Eur. J. Med. Chem. 41 (2006) 445-456
32. Pyo M.K., Lee D.H., Kim D.H., Lee J.H., Moon J.C., Chang K.C., and Yun-Choi H.S. Enantioselective synthesis of (R)-(+)- and (S)-(-)-higenamine and their analogues with effects on platelet aggregation and experimental animal model of disseminated intravascular coagulation. Bioorg. Med. Chem. Lett. 18 (2008) 4110-4114
33. Leoncini G., Signorello M.G., Grosi G.C., and Braccio M.D. Mechanism of action of two new pyrimidoquinoline and isoquinoline derivatives in human platelets. Thromb. Res. 87 (1997) 483-492
34. Shams G., Romstedt K.J., Lust L.A., Clark M.T., Miller D.D., and Feller D.R. β-Adrenergic receptor and platelet inhibitory activities of a new series of trime- toquinol and related benzazepine analogs. Gen. Pharmacol. 28 (1997) 323-330
35. Pyo M.K., Kim J.M., Jin J.L., Chang K.C., Lee D.H., and Yun-Choi H.S. Effects of higenamine and its 1-naphthyl analogs, YS-49 and YS-51, on platelet TXA2 synthesis and aggregation. Thromb. Res. 120 (2007) 81-86
36. Yun-Choi H.S., Pyo M.K., Park K.M., Chang K.C., and Lee D.H. Antithrombotic effects of YS-49 and YS-51-1-naphthylmethyl analogs of higenamine. Thromb. Res. 104 (2001) 249-255
37. Yang J., Hua W.Y., Wang F.X., Wang Z.Y., and Wang X. Design, synthesis, and inhibition of platelet aggregation for some 1-o-chlorophenyl-1,2,3,4-tetrahydroiso- quinoline derivatives. Bioorg. Med. Chem. 12 (2004) 6547-6557
38. Saha S.L., Roche V.F., Pendola K., Kearley M., Lei L., Romstedt K.J., Herdman M., Shams G., Kaisarec V., and Feller D.R. Synthesis and in vitro platelet aggregation and TP receptor binding studies on bicyclic 5,8-ethanoocta- hydroisoquinolines and 5,8-ethanotetrahydroisoquinolines. Bioorg. Med. Chem. 10 (2002) 2779-2793
39. Malovichko O.L., Petrus A.S., Krysko A.A., Kabanova T.A., Andronati S.A., Karaseva T.L., and Kiriyak A.V. Derivatives of 7-amino-1,2,3,4-tetrahydro- isoquinoline and isophthalic acids as novel fibrinogen receptor antagonists. Bioorg. Med. Chem. Lett. 16 (2006) 5294-5297
40. Cabedo N., El Aouad N., Berenguer I., Zamora M., de Arellano M.C.R., Suvire F., Bermejo A., Enriz D., and Cortes D. Efficient synthesis and structural analysis of new dioxopiperazine isoquinolines. Tetrahedron 62 (2006) 4408-4418
41. Sánchez R., Luna H., Pérez H.I., Manjarrez N., and Solís A. Evaluation of animal liver acetone powders for the resolution of 1,2,3,4-tetrahydroisoquinoline-3-car- boxylic acid. Tetrahedron: Asymmetry 12 (2001) 1399-1401
42. 6 antagonists. Bioorg. Med. Chem. 12 (2004) 3977-3985
43. Zhao M., Bi L., Bi W., Wang C., Yang Z., Ju J., and Peng S. Synthesis of new class dipeptide analogues with improved permeability and antithrombotic activity. Bioorg. Med. Chem. 14 (2006) 4761-4774